Pexnib 125mg, containing Pexidartinib Hydrochloride, is a medication manufactured by Pharma Lord. It is primarily used for the treatment of tenosynovial giant cell tumor (TGCT), a rare, non-cancerous tumor that affects the synovium (the lining of the joints and tendons). TGCT can cause joint pain, stiffness, and swelling, which may limit mobility. Pexidartinib Hydrochloride is a tyrosine kinase inhibitor that works by blocking certain proteins (CSF1R, KIT, and FLT3) involved in the abnormal cell growth contributing to TGCT.
Advantages:
- Targeted Therapy: Pexnib specifically targets the CSF1R protein, which is crucial for TGCT cell survival, making it an effective treatment for patients with locally advanced or recurrent TGCT that cannot be cured with surgery.
- Non-Surgical Option: For patients whose tumors are inoperable or surgery poses significant risks, Pexnib offers a non-invasive treatment alternative.
- Improved Mobility: By reducing tumor size and alleviating symptoms like pain and stiffness, Pexnib can improve joint function and mobility.
- Disease Control: Pexnib may help control the progression of TGCT, providing relief from symptoms over the long term.
Uses:
- Treatment of tenosynovial giant cell tumor (TGCT) in adults with severe cases where surgical removal is not a viable option.
- Management of TGCT symptoms such as joint pain, swelling, and stiffness.
- Potential reduction in tumor size and prevention of further damage to joints or tendons.
As always, patients should follow their healthcare provider's recommendations when using Pexnib 125mg. Regular monitoring of liver function is important due to the potential side effects of the drug.